ZURICH (Reuters) - Relief Therapeutics and partner NeuroRx Inc announced on Friday that 150 patients had been enrolled to date in a phase 2b/3 trial of RLF-100 for treating respiratory failure in patients with critical COVID-19.
Relief also said its main shareholder, GEM Global Yield LLC SCS, had exercised 500 million warrants in the company, putting Relief’s available cash balance at around 49.8 million Swiss francs ($54.5 million).
($1 = 0.9144 Swiss francs)
Reporting by Michael Shields; Editing by Caroline Copley
Our Standards: The Thomson Reuters Trust Principles.